SecBot SecBot
424B5 ·Filed Jul 2, 2026

ABVX

Abivax S.A.
BEARISH
Impact 6/10
Horizonimmediate Processed4mo ago SEC0001193125-26-294491
Notable filing: 424B5
Actionable Insight ▼ Bearish

The $800M offering at a 6.2% discount to the prior close ($133.26) creates immediate selling pressure and dilutes existing holders by ~8%. Monitor the stock for continued weakness as the 60-day lock-up on ~1.18M shares from insiders expires. The NDA submission timeline (Q4 2026) is the next major catalyst, but the large cash raise signals management expects significant commercialization costs ahead.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$144.65
T+0 close · Jul 2, 2026 · via day close
Latest settled
−33.05%
T+60 · $96.85
Vs SPY
−36.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $144.65entry
  2. T+1 · 4mo ago −0.46%α −1.33% · $143.99
  3. T+5 · 4mo ago −2.70%α −3.63% · $140.74
  4. T+20 · 4mo ago −14.05%α −13.63% · $124.33
  5. T+60 · 7w ago −33.05%α −36.61% · $96.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abivax is raising approximately $759.8 million in net proceeds through a public offering of 6,400,000 ADSs at $125.00 per ADS, with an underwriter option for an additional 960,000 ADSs. The offering follows positive Phase 3 ABTECT Part 2 data for obefazimod in ulcerative colitis announced on June 29, 2026, and the company plans to submit an NDA in Q4 2026. The substantial dilution (~$110.78 per ADS) and the pre-revenue clinical-stage status make this a bearish event for existing shareholders despite the positive clinical data.

Key Facts

  • Offering of 6,400,000 ADSs at $125.00 per ADS for total gross proceeds of $800,000,000.
  • Net proceeds to Abivax are approximately $759.8 million ($666.8 million), or $874.1 million if underwriters exercise option for 960,000 additional ADSs.
  • New investors will experience immediate dilution of $110.78 per ADS in as adjusted net tangible book value.
  • Pro forma cash position increases to approximately $1.1 billion (€1,105 million) from €438 million as adjusted.
  • Company plans to submit NDA for obefazimod in UC to FDA in Q4 2026 following positive Phase 3 Part 2 data announced June 29, 2026.
  • Net proceeds intended for US commercialization of obefazimod, clinical R&D in UC and Crohn's disease, and general corporate purposes.
  • Underwriters have a 30-day option to purchase up to an additional 960,000 ADSs.
  • Directors and executive officers subject to 60-day lock-up from date of prospectus supplement.

Financial Impact

Gross proceeds of $800 million from 6,400,000 ADSs at $125.00 per ADS; net proceeds ~$759.8 million. Immediate dilution of $110.78 per ADS for new investors.

dilutioncashshare count

Risk Factors

  • Substantial immediate dilution of $110.78 per ADS for new investors.
  • Potential for further dilution from outstanding warrants and free shares (8.6M+ shares).
  • Clinical-stage biotech with no product revenue; NDA submission and FDA approval are binary events.
  • 60-day lock-up expiration on ~1.18M insider shares could add selling pressure.
  • French foreign investment control regulations may limit non-EU investor participation.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-294491
Document: d111359dexfilingfees.htm0001193125-26-294491
Document: 0001193125-26-294491-index-headers.html0001193125-26-294491
Document: 0001193125-26-294491-index.html0001193125-26-294491
Document: 0001193125-26-294491.txt0001193125-26-294491

Track record

10 reports on ABVX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $87.58 +5.01% settles Nov 24
  2. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $87.58 +1.14% ▼ −0.99% +1.71% vs SPY
  3. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $87.58 −32.63% ▼ −6.58% −7.79% vs SPY
  4. Jul 2, 202619w ago 6-K Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
  5. Jul 2, 202619w ago 424B5 Bearish 6/10 Viewing Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
  6. Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $87.58 +33.93% ▼ −7.25% −6.99% vs SPY
  7. Jun 29, 202620w ago 6-K Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
  8. Jun 29, 202620w ago Press Release Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
  9. May 22, 202625w ago Press Release Neutral 5/10 Entry $126.41 to $129.69 Now $87.58 −30.72% ▲ +2.59% +1.51% vs SPY
  10. Mar 23, 202634w ago Press Release Mixed 6/10 Entry $110.17 to $111.35 Now $87.58 −20.50% ▲ +1.07% +1.49% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (12h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026